# OnCo record nasopharyngeal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/nasopharyngeal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "nasopharyngeal" ;
  schema:name "Nasopharyngeal carcinoma"@en ;
  schema:alternateName "NPC"@en ;
  schema:description "A cancer at the back of the nose caused largely by the Epstein-Barr virus and common in southern China and Southeast Asia. Radiation cures most early cases; adding chemotherapy and, recently, PD-1 immunotherapy has improved outcomes in advanced disease, and a blood test for viral DNA can detect it early."@en ;
  schema:url <https://onco.cc/cancers/nasopharyngeal/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nasopharyngeal_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1693598> ;
  schema:citation <https://doi.org/10.1200/JCO.20.03237>, <https://doi.org/10.1056/NEJMoa1701717>, <https://www.cancer.gov/types/head-and-neck/patient/adult/nasopharyngeal-treatment-pdq> ;
  onco:tag "gap-fill", "head-and-neck", "viral" ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/tors/>, <https://onco.cc/technologies/tcr-t/>, <https://onco.cc/technologies/acupuncture-xerostomia/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/akeso/>, <https://onco.cc/companies/hengrui/>, <https://onco.cc/companies/beone/> ;
  onco:institutions <https://onco.cc/institutions/sysucc/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/re-irradiation/> ;
  onco:trials <https://onco.cc/trials/taishan-301/>, <https://onco.cc/trials/nct05294172/>, <https://onco.cc/trials/nct06976190/>, <https://onco.cc/trials/nct06118333/>, <https://onco.cc/trials/nct04974398/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chan-n-engl-j-med/> ;
  onco:journals <https://onco.cc/journals/tumour-virus-research/> ;
  onco:pipeline <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/yl201/>, <https://onco.cc/drugs/kl-a167/>, <https://onco.cc/drugs/mrg003/>, <https://onco.cc/drugs/hmbd-001/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/tors/> .